Увійти

Готові списки джерел за темами / 347.965.31 (043.2)

Зміст

Статті в журналах

Добірка наукової літератури з теми "347.965.31 (043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "347.965.31 (043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "347.965.31 (043.2)"

1

Medić, Snežana, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković, et al. "Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia." JAMA Network Open 6, no. 2 (2023): e2255779. http://dx.doi.org/10.1001/jamanetworkopen.2022.55779.

Повний текст джерела

Анотація:

ImportanceDuring the COVID-19 pandemic, children and adolescents were massively infected worldwide. In 2022, reinfections became a main feature of the endemic phase of SARS-CoV-2, so it is important to understand the epidemiology and clinical impact of reinfections.ObjectiveTo assess the incidence, risk, and severity of pediatric SARS-CoV-2 reinfection.Design, Setting, and ParticipantsThis retrospective cohort study used epidemiologic data of documented SARS-CoV-2 infections from the surveillance database of the Institute for Public Health of Vojvodina. A total of 32 524 children and adolescen

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Herrero-Morant, A., J. L. Martín-Varillas, S. Castañeda, et al. "POS1371 BIOLOGICAL THERAPY IN REFRACTORY NEUROBEHÇET’S DISEASE. MULTICENTER STUDY OF 42 PATIENTS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 967–68. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3407.

Повний текст джерела

Анотація:

Background:Neuro-Behçet’s disease (NBD) is a severe complication of Behcet’s disease (BD). Despite well-established therapies with glucocorticoids and conventional immunosuppressants (cIS), a significant proportion of patients are refractory.Objectives:To assess efficacy and safety of biologic therapy (BT) in NBD refractory to glucocorticoids and at least one cIS.Methods:Open-label multicenter study of refractory NBD from 23 different referral Spanish Hospitals. Main outcome was neurological response. Secondarily, analytical efficacy was measured by Erythrocyte Sedimentation Rate (ESR), C-Reac

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Skripochnik, Edvard, Robert E. Michler, Viktoria Hentschel, and Siyamek Neragi-Miandoab. "The Efficacy and Outcome of Ministernotomy Compared to Those of Standard Sternotomy for Aortic Valve Replacement." ISRN Minimally Invasive Surgery 2014 (February 19, 2014): 1–6. http://dx.doi.org/10.1155/2014/254084.

Повний текст джерела

Анотація:

Background. Benefits of ministernotomy have been reported but not yet fully established in the current literature. Ministernotomy may be associated with less bleeding, less need for transfusion, and reduced hospital length of stay. Methods. We retrospectively evaluated 347 patients who underwent aortic valve replacement between 2007 and 2011 at our institution. Results. Standard sternotomy was performed in 303 patients (154 males, 50.8% and 149 females, 49.2%) and ministernotomy in 44 patients (13 males, 30% and 30 females, 70%); most of the patients in ministernotomy group were female (75%) (

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Dunlop, Hayley, Evelyn Fitzpatrick, Kevin Kurti, et al. "Participation of Patients From Racial and Ethnic Minority Groups in Phase 1 Early Cancer Drug Development Trials in the US, 2000-2018." JAMA Network Open 5, no. 11 (2022): e2239884. http://dx.doi.org/10.1001/jamanetworkopen.2022.39884.

Повний текст джерела

Анотація:

ImportanceDespite federal initiatives encouraging the enrollment of individuals from racial and ethnic minority groups in US clinical trials, no studies to date have specifically examined demographic disparities among participants in phase 1 drug development trials for patients with metastatic cancer.ObjectiveTo assess trends in the enrollment of patients from racial and ethnic minority groups in US phase 1 therapeutic drug trials for metastatic cancer from 2000 to 2018.Design, Setting, and ParticipantsIn this cross-sectional study, ClinicalTrials.gov was queried in July 2021 to identify compl

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Wen, Hao, Qin Xu, Xiujie Sheng, Huawen Li, Xipeng Wang, and Xiaohua Wu. "Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers." JAMA Network Open 6, no. 7 (2023): e2326437. http://dx.doi.org/10.1001/jamanetworkopen.2023.26437.

Повний текст джерела

Анотація:

ImportanceUnderstanding germline and somatic status in patients with gynecologic cancers could improve risk assessment and guide therapeutic decision-making.ObjectiveTo evaluate the prevalence and landscape of germline pathogenic or likely pathogenic (P/LP) variants and explore whether these variants are associated with somatic phenotypes and cancer risk in unselected patients with gynecologic cancers.Design, Setting, and ParticipantsThis cross-sectional study retrospectively enrolled unselected patients in China with a gynecologic cancer, including ovarian, cervical, and endometrial, who unde

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Choe, Hannah, Amandeep Salhotra, Nosha Farhadfar, et al. "Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study." Blood 144, Supplement 1 (2024): 98. https://doi.org/10.1182/blood-2024-209965.

Повний текст джерела

Анотація:

Introduction: Chronic graft-versus-host disease (cGVHD) is characterized by inflammatory and fibrotic pathology affecting multiple organs and leading to significant impairment. Axatilimab (AXA), an anti-colony-stimulating factor 1 receptor monoclonal antibody, targets monocytes and macrophages that are critical for inflammation and fibrosis in cGVHD. In the pivotal, phase 2 AGAVE-201 study (NCT04710576), AXA had robust clinical activity and was generally well tolerated in patients with cGVHD, with adverse events that were mostly low grade, reversible, and dose dependent (Wolff D, et al. Blood.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Pathak, Surabhi, Romy Jose Thekkekara, Ahmed T. Ahmed, et al. "Real world outcomes of upfront docetaxel for hormone naïve metastatic prostate cancer in an ethnically diverse inner-city population." Journal of Clinical Oncology 36, no. 6_suppl (2018): 359. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.359.

Повний текст джерела

Анотація:

359 Background: Upfront docetaxel (UD) in castration-sensitive metastatic prostate cancer (CSPC) has improved failure-free and overall survival in the CHAARTED, GETUG-AFU 15 and STAMPEDE trials, resulting in a paradigm shift in practice patterns. However, the impact of docetaxel-based chemotherapy regimens in minorities and in real-world practice remains to be described. The objective of this study is to evaluate tolerability and response to UD in an inner-city ethnically diverse CSPC cohort. Methods: We retrospectively reviewed clinical data for CSPC patients at Cook County Hospital. Patients

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Sierra-Díaz, Diana Carolina, Adrien Morel, Dora Janeth Fonseca, et al. "Abstract P3-07-05: Genetic profile of germline mutations in unselected women with breast cancer in a Colombian population." Cancer Research 82, no. 4_Supplement (2022): P3–07–05—P3–07–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-07-05.

Повний текст джерела

Анотація:

Abstract Introduction In Colombia Breast cancer (BC), is the most frequent and has the highest mortality rate among all types of cancer. There are few studies of the genomic profile in unselected affected population by BC in Colombia. Some of these studies have only tested the presence of variants reported as founders named “Colombian Profile”.We conducted a large-scale genomic analysis using Whole Exome Sequencing (WES) to evaluate germline mutations in unselected BC patients. Methods This trial included 299 unselected BC female patients aged over 18 years old, without personal and family his

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Dörner, T., Y. Tanaka, M. Mosca, et al. "POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 639.1–639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2375.

Повний текст джерела

Анотація:

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).ObjectivesTo assess the safety profile of BARI in patients with SLE.MethodsPatients with SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in one 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616964).ResultsA total of 1,849 patients were

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Wang, Yakun, Yongsheng Li, Jiyan Liu, et al. "SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14668-e14668. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14668.

Повний текст джерела

Анотація:

e14668 Background: Although marketed antibodies against PD-1/L1 or CTLA-4 have been shown to be efficacious in a variety of tumors, the overall response rate (ORR) remains low. SI-B003 is a PD-1/CTLA-4 bispecific antibody. We hypothesized that co-targeting PD-1 and CTLA-4 simultaneously could achieve a better anti-tumor activity due to cooperative binding to exhausted T-cell subsets. Methods: Patients with recurrent or metastatic solid tumors who had failed standard therapy were eligible to participate. SI-B003 was administered intravenously every other week (Q2W) in a four-week cycle. The pha

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!